Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges
Jeremy Chataway, Thomas Williams, Vivien Li, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 3, pp. 277-301
Open Access | Times Cited: 25

Showing 25 citing articles:

The neuropathobiology of multiple sclerosis
Marcel S. Woo, Jan Broder Engler, Manuel A. Friese
Nature reviews. Neuroscience (2024) Vol. 25, Iss. 7, pp. 493-513
Closed Access | Times Cited: 32
Blood–Brain Barrier Disruption in Neuroimmunological Disease
Fumitaka Shimizu, Masayuki Nakamori
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10625-10625
Open Access | Times Cited: 4
Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis
Mar Barrantes-Cepas, Samantha Noteboom, Elisa Colato, et al.
Multiple Sclerosis Journal (2025)
Closed Access
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?
Sílvia Susin-Calle, José Rodríguez, Elvira Munteis, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Transcriptomic profiling identifies ferroptosis and NF-κB signaling involved in α-dimorphecolic acid regulation of microglial inflammation
Xiaolan Zhu, Peijuan Wang, Chao Shan, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Rationnel et stratégie d’utilisation des traitements de fond de la sclérose en plaques
Laurent Magy
Actualités Pharmaceutiques (2025) Vol. 64, Iss. 644, pp. 29-34
Closed Access
Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials
Winston Dzau, Izanne Roos, Tomáš Kalinčík
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335495
Closed Access
Multiple sclerosis in china: the current state of diagnosis and management
Dongmei Jia, Fu‐Dong Shi, Wei Jiang
Current Opinion in Neurology (2025)
Closed Access
Current challenges in secondary progressive multiple sclerosis: diagnosis, activity detection and treatment
Luís Brieva, Carmen Calles, Lamberto Landete, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Be at the table or be on the menu
Sarah Hughes, Paula Blackall, Jennifer Slough, et al.
British Journal of Neuroscience Nursing (2025) Vol. 21, Iss. Sup 1a, pp. S27-S29
Closed Access
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Blood-Brain Barrier Disruption in Neuroimmunological Disease
Fumitaka Shimizu, Masayuki Nakamori
(2024)
Open Access | Times Cited: 3
Investigating cortical hypoxia in multiple sclerosis via time‐domain near‐infrared spectroscopy
Thomas Williams, Frédéric Lange, Kenneth J. Smith, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 9, pp. 2372-2381
Open Access | Times Cited: 2
Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review
Hibba Yousef, Brigitta Malagurski Tortei, Filippo Castiglione
Journal of Neurology (2024)
Open Access | Times Cited: 2
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
James Blackstone, Thomas Williams, Jennifer Nicholas, et al.
BMJ Open (2024) Vol. 14, Iss. 9, pp. e086414-e086414
Open Access | Times Cited: 2
CD4+ Trm sustain the chronic phase of auto-immune neuroinflammatory disease
Aurora Pignata, David Frieser, Cheng‐Chih Hsiao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Genetically predicted associations between circulating cytokines and autoimmune diseases: a bidirectional two-sample Mendelian randomization
Jie Jie, Yonglu Gong, Songquan Luo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis
Peter K. Stys, Shigeki Tsutsui, Arie Gafson, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access | Times Cited: 1
Circulating inflammatory proteins and risk of Parkinson’s disease and other neurodegenerative disorders: a two-sample Mendelian randomization study
Zhichun Chen, Guanglu Li, Liche Zhou, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Circulating inflammatory proteins and risk of Parkinson’s disease and other neurodegenerative disorders: a two-sample Mendelian randomization study
Zhichun Chen, Guanglu Li, Liche Zhou, et al.
Research Square (Research Square) (2024)
Open Access
Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population
Sean Apap Mangion, Jeremy Chataway
Advances in Clinical Neuroscience & Rehabilitation (2024)
Closed Access
Molecular Targeted Therapies in Systemic Autoimmune Diseases
Yoshiya Tanaka
Springer eBooks (2024), pp. 1-14
Closed Access
Brain atrophy assessment in multiple sclerosis: technical– and subject-related barriers for translation to real-world application in individual subjects
Robert Zivadinov, Ashley Tranquille, Jack A. Reeves, et al.
Expert Review of Neurotherapeutics (2024), pp. 1-16
Closed Access
Selecting informative patients for phase 2 progressive trials in MS: Design considerations for phase 2 clinical trials in progressive MS
Marcus Koch, Carlos R. Cámara-Lemarroy, Eva Strijbis, et al.
Multiple Sclerosis Journal (2024)
Closed Access
Molecular Targeted Therapies in Systemic Autoimmune Diseases
Yoshiya Tanaka
(2024), pp. 537-550
Closed Access
Page 1

Scroll to top